ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

Pfizer seeks approval for COVID-19 pill in Japan

Paxlovid would be 2nd oral drug for mild cases in the country

Pfizer is seeking approval of its COVID-19 pill from Japanese authorities. (Handout photo from Pfizer)   © Reuters

TOKYO (Kyodo) -- Pfizer Japan Inc. said Friday it has applied to the Japanese health ministry for approval of its COVID-19 pill which, if granted, would make it the second oral drug for mild coronavirus cases available in the country.

The new drug application for Paxlovid, a combination of two antiviral drugs nirmatrelvir and ritonavir, comes at a time when Japan is battling its sixth surge of COVID-19 cases amid a spread of the Omicron variant, with Japan already agreeing to procure enough of the drug for 2 million people.

Prime Minister Fumio Kishida said earlier in the week a final agreement with the Japanese arm of U.S. pharmaceutical giant Pfizer Inc. on the drug's purchase is expected by the end of January, aiming for its approval in February.

The Ministry of Health Labor and Welfare has already approved the oral drug molnupiravir, developed by U.S. pharmaceutical company Merck & Co. in December.

Health minister Shigeyuki Goto said in December that oral drugs are expected to play a significant role in treating sufferers of mild COVID-19 symptoms.

Clinical trials have shown that Paxlovid has a higher chance of preventing hospitalizations and deaths compared to molnupiravir, cutting such risks by 88 percent for patients who took the drug within five days of the onset of symptoms, compared to those who were given a placebo, according to the company

The pill, which prevents the coronavirus from multiplying in the body, is prescribed to be taken twice a day for five days.

It has been approved in Britain and was authorized in the United States in December for emergency use.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more